Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evolution of genotypic resistance to nucleoside analogues in patients receiving protease inhibitor-containing regimens.

Antiviral therapy - 1 Jan 1999

Pèrez-Olmeda M, Rubio A, Puig T, Gômez-Cano M, Ruiz L, Leal M, Clotet B, Soriano V

Abstract excerpt

The prevalence of genotypic resistance to nucleoside analogues (NA) was examined using a line probe assay (LiPA, Innogenetics, Spain) and a point mutation assay to test for codon 151 polymorphism in plasma from 34 individuals who had been exposed to NA for longer than 1 year. The testing was repeated in the same population after 6 months of being on a new potent protease inhibitor (PI)-containing antiretroviral...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acquired Immunodeficiency Syndrome
Share to Anti-HIV Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Viral

Share to Drug Therapy, Combination

Share to HIV Protease Inhibitors

Share to Nucleosides

Source

Identifiers

PMID: 12731758

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evolution of genotypic resistance to nucleoside analogues in patients receiving protease inhibitor-containing regimens.PMID 12731758Read ↗

Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain.Semantic proximity Read ↗

Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in SpainSemantic proximity Read ↗

Presence of genotypic resistance in nucleoside analogue-treated HIV-1-infected patients with undetectable viral load.Semantic proximity Read ↗

Prevalence of genotypic resistance to nucleoside analogues and protease inhibitors in Spain. The ERASE-2 Study Group.Semantic proximity Read ↗

Human immunodeficiency virus 1 strains resistant to nucleoside inhibitors of reverse transcriptase in isolates from the Czech Republic as monitored by line probe assay and nucleotide sequencing.Semantic proximity Read ↗

Prevalence of genotypic resistance to nucleoside analogues and protease inhibitors in antiretroviral-naive HIV patients in Campania, Italy.Semantic proximity Read ↗

Emergence of antiretroviral drug resistance in therapy-naive HIV infected patients in Hungary.Semantic proximity Read ↗

Decline in the rate of genotypic resistance to antiretroviral drugs in recent HIV seroconverters in Madrid.Semantic proximity Read ↗

Longitudinal use of a line probe assay for human immunodeficiency virus type 1 protease predicts phenotypic resistance and clinical progression in patients failing highly active antiretroviral therapy.Semantic proximity Read ↗

Primary HIV-1 drug resistance in Spain before and after the introduction of protease inhibitors.Semantic proximity Read ↗

Prevalence of mutation associated to resistance with nucleoside analogues in a cohort of naïve HIV-1 positive subjects during the period 1984-1997.Semantic proximity Read ↗

Evaluation of mixtures of wild-type HIV-1 and HIV-1 with resistance point mutations against reverse transcriptase inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.